OM
Opaleye Management Portfolio holdings
AUM
$494M
1-Year Return
68.17%
This Quarter Return
+109.06%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$510M
AUM Growth
+$233M
(+84%)
Cap. Flow
+$74.8M
Cap. Flow
% of AUM
14.68%
Top 10 Holdings %
Top 10 Hldgs %
42.94%
Holding
56
New
7
Increased
29
Reduced
8
Closed
9
Top Buys
| 1 |
APTO
Aptose Biosciences, Inc.
APTO
|
$19.1M |
| 2 |
Ocular Therapeutix
OCUL
|
$9.21M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$8.12M |
| 4 |
EDAP
EDAP TMS
EDAP
|
$6.58M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$6.43M |
Top Sells
| 1 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$8.04M |
| 2 |
Cytokinetics
CYTK
|
$7.4M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$4.79M |
| 4 |
THOR
Synthorx, Inc. Common Stock
THOR
|
$2.93M |
| 5 |
NextCure
NXTC
|
$2.62M |
Sector Composition
| 1 | Healthcare | 90.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
FLXN
26
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $8.6M | 1.69% |
415,500
+310,500
| +296% | +$6.43M |
|
|
BPMC
27
DELISTED
Blueprint Medicines
BPMC
| $8M | 1.57% |
100,000
-5,000
| -5% | -$400K |
|
28
Zymeworks
ZYME
$1.09B
| $7.96M | 1.56% |
175,000
+5,000
| +3% | +$227K |
|
|
EDAP
29
EDAP TMS
EDAP
$90.5M
| $7.91M | 1.55% |
1,785,000
+1,485,000
| +495% | +$6.58M |
|
|
TCDA
30
DELISTED
Tricida, Inc. Common Stock
TCDA
| $7.3M | 1.43% |
194,000
-1,000
| -0.5% | -$37.6K |
|
31
Dianthus Therapeutics
DNTH
$778M
| $6.73M | 1.32% |
28,122
+4,059
| +17% | +$971K |
|
32
Crinetics Pharmaceuticals
CRNX
$3.17B
| $6.68M | 1.31% |
266,100
+59,100
| +29% | +$1.48M |
|
|
RARX
33
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $6.66M | 1.31% |
141,800
| – | – |
|
34
TG Therapeutics
TGTX
$4.97B
| $6.43M | 1.26% |
579,651
-32,849
| -5% | -$365K |
|
35
FibroGen
FGEN
$47.2M
| $6.26M | 1.23% |
5,840
-160
| -3% | -$172K |
|
|
ACHN
36
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $4.58M | 0.9% |
+760,000
| New | +$4.58M |
|
37
Aquestive Therapeutics
AQST
$575M
| $4.3M | 0.84% |
+738,500
| New | +$4.3M |
|
|
KDMN
38
DELISTED
Kadmon Holdings, Inc.
KDMN
| $4.26M | 0.84% |
+940,373
| New | +$4.26M |
|
|
RDUS
39
DELISTED
Radius Health, Inc.
RDUS
| $3.39M | 0.66% |
168,000
+93,000
| +124% | +$1.87M |
|
40
Quanterix
QTRX
$201M
| $3.12M | 0.61% |
132,200
-52,800
| -29% | -$1.25M |
|
41
Rhythm Pharmaceuticals
RYTM
$6.83B
| $2.54M | 0.5% |
+110,500
| New | +$2.54M |
|
42
TELA Bio
TELA
$65.8M
| $2.27M | 0.44% |
+175,000
| New | +$2.27M |
|
43
MacroGenics
MGNX
$117M
| $2.18M | 0.43% |
+200,500
| New | +$2.18M |
|
44
Fennec Pharmaceuticals
FENC
$248M
| $78K | 0.02% |
+12,000
| New | +$78K |
|
45
Protara Therapeutics
TARA
$123M
| $75K | 0.01% |
4,704
+3,354
| +248% | +$53.5K |
|
|
BLRX
46
BioLineRX
BLRX
$14.7M
| $38K | 0.01% |
417
| – | – |
|
47
Assembly Biosciences
ASMB
$177M
| – | – |
-4,167
| Closed | -$492K |
|
|
48
Cytokinetics
CYTK
$6.02B
| – | – |
-650,000
| Closed | -$7.4M |
|
|
49
NextCure
NXTC
$13.3M
| – | – |
-7,083
| Closed | -$2.62M |
|
|
TVRD
50
Tvardi Therapeutics, Inc. Common Stock
TVRD
$277M
| – | – |
-12,222
| Closed | -$8.04M |
|